Connor Iapoce

At AAO 2023, David Lally, MD describes results from the phase 2 ARCHER study and the potential benefit of intravitreal ANX007 for patients with GA.

Lowering blood pressure significantly reduced the risk of developing dementia among adults with hypertension in China compared to usual care.

The phase 2 KARDIA-1 study reports a single dose of zilebesiran safely reduced systolic blood pressure in people with mild-to-moderate hypertension for up to 6 months.

Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.

Phase 3 results from the GATHER2 trial show the treatment effect of avacincaptad pegol for geographic atrophy more than doubled over 2 years compared to year 1 of study.

Presented at AAO 2023, new data show dual Ang-2/VEGF-A inhibition with faricimab improved pigment epithelial detachment outcomes versus aflibercept.

In a pooled subcohort analysis of YOSEMITE and RHINE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.

Presented at AAO 2023, a retrospective study found no statistically significant difference in retinopathy worsening between GLP-1 RAs and SGLT2 inhibitors.

Six-month RIPPLE-1 results show treatment with the IBE-814 intravitreal implant led to CST reduction and BCVA improvement in patients with DME or RVO.

Presented at AAO 2023, first-time results suggest home OCT may have a significant effect on treatment burden in the management of nAMD.

First-year results from ALTITUDE suggest RGX-314 was well-tolerated and provided meaningful improvements in disease severity at dose levels 1 and 2.

On the floor at AAO 2023, host Veeral Sheth, MD, discusses UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.

Presented at AAO 2023, new 3-year data from the GALE extension study shows increasing treatment effects over time with pegcetacoplan injection for geographic atrophy.

In a presentation at AAO 2023, Tsang discussed topline data from the phase 2 trial on MCO-010 optogenetic therapy for vision loss in Stargardt Disease.

Results from the phase 2/3 DIAMOND trial show a significant reduction in central macular thickness and significant visual gain in eyes treated with OCS-01 drops versus sham.

New, 2-year results from the phase 3 PHOTON study show continued benefit for patients with diabetic macular edema treated with aflibercept 8mg.

The post hoc analysis of the phase 3 YOSEMITE/RHINE trials may support the therapeutic role of dual Ang-2/VEGF-A inhibition with faricimab for DME.

A post hoc analysis of the phase 3 YOSEMITE and RHINE trials found significantly more patients had leakage resolution with faricmab than with aflibercept at Week 16.

Results from the phase 3 YOSEMITE and RHINE trials show more than half of faricimab treat-and-extend patients met the criteria for a potential every-20-week dosing extension.

John W. Ostrominski, MD, describes the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults over a 20-year period.

Patients with RAO had a higher risk of death, stroke, and myocardial infarction at both short-term and long-term intervals compared to matched controls diagnosed with cataract.

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.

12-month GATHER2 results show monthly avacincaptad pegol 2 mg was well tolerated and showed significantly slower geographic atrophy growth than sham treatment.

On October 27, 2023, the FDA warned consumers to stop using ophthalmic products from 6 brands, including CVS Health and Rite Aid, after investigators found bacterial contamination at a manufacturing facility.

Scleral buckling without PPV is effective for most patients with retinal dialysis and shows a low rate of cataract formation.

Most answers provided by ChatGPT-4 were consistently appropriate regarding vitreoretinal surgeries, including retinal detachments, macular holes, and epiretinal membranes.

Results from a large observational retrospective cohort of ≥500 patients with PsA show relatively low drug persistence of apremilast, an oral PDE4 inhibitor.

24-week results from the UPREAL show higher efficacy of upadacitinib among males with PsA, bio-naïve patients, and those with elevated baseline C-reactive protein.

A deep learning system using ultra-widefield fundus imaging exhibited relatively good performance in detecting 5 common retinal lesions in rural areas.

Utilizing swept-source OCT, the analysis reports significantly thicker subfoveal choroidal thickness among patients with active disease than those with inactive disease.